With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Gubra’s once-weekly obesity candidate was tied to 3% weight loss during a six-week phase 1 trial ... a combination of ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

We're living in a world full of foods that trigger constant hunger, cravings and thoughts about eating. Is it even possible ...

Andme Holding Co ( (ME) ) has released its Q2 earnings. Here is a breakdown of the information 23Andme Holding Co presented to its investors.

With the rising popularity of telehealth providers offering GLP-1 medications ... or liquid drops, typically in a daily ...

Olfactive Biosolutions, the leader in harnessing food molecules for the treatment of chronic diseases, has begun production of its Protenx™ GLP-1/GIP Weight Loss patented weight loss and blood sugar ...

The company’s lead product is a long-acting GLP-1 drug known as MET-097i. In a Phase 1 trial, five weekly injections of the ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

GLP-1 receptor agonists ... to believe willpower alone is insufficient for long-term weight loss, making them potentially ...

The correlation between the rise of these appetite-suppressing drugs and the decline in snack sales suggests that as more ...